Johnson & Johnson anticipates $400 million in tariff costs due to China trade tensions, affecting its medical technology units. CEO warns of supply chain issues and advocates for t...
Johnson & Johnson expects to face $400 million in tariff costs this year, largely due to the trade war with China, affecting its medical technology units. CEO Joaquin Duato warns o...
Johnson & Johnson announces a 2.4% increase in Q1 sales to $21.9 billion, exceeding market expectations. Earnings per share and net earnings saw significant growth, with leadership...
Johnson & Johnson announces a 2.4% increase in Q1 sales to $21.9 billion, exceeding expectations. Earnings per share and net earnings see over 237% growth, highlighting the company...
Johnson & Johnson announced a 2.4% increase in Q1 sales to $21.9 billion, exceeding expectations. Earnings per share and net earnings saw dramatic increases, with the CEO highlight...
Johnson & Johnson announced a 2.4% increase in Q1 sales to $21.9 billion, exceeding expectations. Earnings per share and net earnings saw significant growth, with leadership expres...
Johnson & Johnson announces a 2.4% increase in Q1 sales to $21.9 billion, exceeding expectations. Earnings per share and net earnings see over 237% growth, with leadership expressi...
Johnson & Johnson's shares fell 3% after a U.S. judge rejected its $10 billion settlement to resolve talc-related cancer lawsuits, marking its third failed attempt and highlighting...
Johnson & Johnson's shares dropped over 3% after a US judge rejected its $10 billion settlement to resolve talc-related cancer lawsuits, marking its third failed attempt. The compa...
Johnson & Johnson's shares fell over 3% after a US judge rejected its $10 billion settlement proposal for talc-related lawsuits, marking its third failed attempt to resolve the lit...
Johnson & Johnson's shares dropped 3% after a judge rejected its $10 billion talc lawsuit settlement proposal, marking its third failed attempt to resolve the litigation through ba...
Johnson & Johnson's shares fell over 3% after a judge rejected its $10 billion talc settlement proposal, marking its third failed attempt to resolve lawsuits alleging its products ...
Johnson & Johnson's shares fell 3% after a judge rejected its $10 billion settlement proposal for talc-related cancer lawsuits, marking another legal setback for the company.
Johnson & Johnson's shares fell over 3% after a US judge rejected its $10 billion settlement offer for talc-related lawsuits, marking its third failed attempt to resolve the litiga...
Johnson & Johnson's shares dropped over 3% after a U.S. judge rejected its $10 billion settlement proposal for talc-related lawsuits, marking its third failed attempt to resolve th...
Johnson & Johnson announces a 25% increase in US investments, exceeding $55 billion over four years, including a new high-tech facility in North Carolina and expansions in manufact...
Johnson & Johnson announced a 5.3% increase in Q4 sales to $22.5 billion, slightly above expectations. Despite a dip in quarterly EPS, the company saw a 4.3% rise in annual sales a...
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies Inc. for $14.6 billion, aiming to enhance its neuroscience portfolio and advance treatment for neuropsychiatric and...
Johnson & Johnson has announced a cash dividend of $1.24 per share for Q1 2025, payable on March 4 to shareholders recorded by February 18. The announcement led to a 0.40% rise in ...
